LongeVC

Longevity is not about the future—it’s about what we can do today. That’s the focus of The Livelong Experience, an exclusive event organized by Livelong Media™ in Palm Beach, Florida, on March 28th and 29th. The event will bring together leading voices from the industry to cover everything from scientific breakthroughs and healthspan optimization to the future of senior living and caregiving. LongeVC’s Managing Partner and Head of Investor relations Aurora Griffin will take the stage twice: 👉 Day 1: A discussion with Brad Inman on the challenges and choices of aging, caregiving, and finding the right home for the golden years. 👉 Day 2: A panel on “The Magic Longevity Pill” with Chris Mirabile from NOVOS, exploring the most promising biotech innovations tackling age-related diseases. The event, hosted at the Palm House Hotel, is designed to bridge the gap between scientific discovery and real-world application, featuring experts across biotech, medicine, and nutrition. Interested in attending? Use code "Aurora" for a registration discount.  More details here: https://lnkd.in/gR9kzGsQ

LongeVC is proud to support the Oxford Venture Capital Network's #BioInnovate 2025 Symposium - an event designed to connect young, bright minds of the next generation of innovators. In the full day of knowledge sharing directly from industry practitioners, LongeVC’s Managing and Founding Partner, Sergey Jakimov, will be delivering a keynote speech at Stevenage Bioscience Catalyst, offering our take into the longevity industry’s arena from a venture capital perspective. If you're interested in discussing longevity, hit us up in DMs to arrange a chat over a cup of coffee!

Staying at the forefront of longevity trends, LongeVC and its sister fund AniVC continue to scale. Today, we are happy to announce that Aurora Griffin has joined our funds as managing partner and head of investor relations, leading fundraising efforts. She will focus on scaling LongeVC II, the firm’s $250M fund dedicated to longevity and age-related diseases, as well as developing AniVC’s $35M fund I. Aurora brings experience across venture capital, private equity, real estate, and wealth management. Previously, she was VP at Bernstein Private Wealth Management, managing investments for high-net-worth clients and institutions. She has also held roles in private equity at Torana Group and capital acquisitions at Griffin Living. Beyond finance, Aurora has a background in policy and academia. She served as a strategy and policy advisor at the U.S. Department of State and was a professor of communications and entrepreneurship at The Catholic University of America. Aurora holds an MBA from Stanford University Graduate School of Business, an MPhil in Theology from University of Oxford as a Rhodes Scholar, and an AB in Classics from Harvard University. She is also a published author. Her expertise will strengthen LongeVC and Ani.VC’s capital strategy as both funds expand their investment focus in biotech, longevity, and animal health. Happy to have you on the team, Aurora!

LongeVC Managing and Founding Partner, Sergey Jakimov, will be taking the stage at the #LongevityScienceSummit to share our insights on the longevity industry’s investment landscape from a venture capital perspective. Longevity Science Foundation, a U.S.-based non-profit and strategic partner of LongeVC, focuses on identifying and funding breakthrough early-stage longevity technologies. The inaugural summit in Miami aims to spotlight the research on healthy human longevity while bringing together the local community for a day of networking. Whether you’re a startup founder, investor, or simply passionate about longevity, feel free to reach out for a cup of coffee in Miami. More detailed info and tickets are available here: https://lnkd.in/dzy_-Y6T

Over 60% of approved drugs, from antibiotics to cancer treatments, originate from compounds found in nature. Yet, the challenge has always been modifying these molecules efficiently for drug development. Unnatural Products Inc., a LongeVC portfolio company, is leading this shift. Unnatural Products Inc. specializes in creating new, unique chemical compounds that don’t naturally exist in nature. These compounds are designed to overcome the drug discovery challenge - 70% of drug targets are complex and difficult to address with traditional small molecules or biologics. Founded by the University of California, Santa Cruz alumni Cameron Pye and Joshua Schwochert, and now backed by a $220M+ research collaboration with Merck, UNP is developing AI-powered approaches to design macrocyclic molecules—synthetic versions of nature’s most effective drug-like compounds. Their technology has the potential to accelerate drug discovery for diseases that have been historically difficult to target, offering new solutions in oncology and beyond. Read more about their journey in a recent article at UCSC: https://lnkd.in/ddGmRjNS 

Sergey Jakimov, co-founder and partner at LongeVC, recently shared his take on the longevity science philosophy on The Microdose Diet podcast with Peggy Van de Plassche, “Why live a long life if it’s not a life worth living?” Our investment philosophy is clear: pragmatic focus on disease-modifying treatments for age-related conditions like cancer, neurodegenerative disorders, and cardiovascular disease. In a conversation with Peggy, Sergey explained that by addressing specific diseases, the field can deliver measurable results and meaningful outcomes—setting the foundation for systemic breakthroughs. The conversation also touched on the role of investors in shaping this field. “You cannot pragmatically invest in aging without being specific enough with disease indications. That doesn't mean we don’t want to cure aging. What we think is that aging as a process is something that happens in the background, and that is something that is so systemic and so holistic that is very hard to pinpoint something to start with, to start tackling it,” Sergey said. Listen to the full episode here: https://lnkd.in/dFR9MvDX

Longevity science is advancing rapidly—but translating those breakthroughs into real-world impact requires collaboration and visionary thinking. Last week, the Stanford Applied Longevity Translation Symposium at Stanford University brought together some of the brightest minds in biotech, academia, and venture capital to explore how we can bridge the gap between research and application in longevity. The event, co-organized by LongeVC and our Operating partner Artem A. Trotsyuk, featured deep discussions on the future of regenerative medicine, age-related therapies, and biotech innovation. Vittorio Sebastiano, co-founder of Turn Biotechnologies, one of LongeVC’s portfolio companies, was one of the panelists, together with Christin Glorioso, MD PHD from NeuroAge Therapeutics and Jean Herbert from Advanced Research Projects Agency for Health (ARPA-H)    At LongeVC, we believe events like this are vital for fostering the partnerships and discussions that will define the next era of healthy aging. A huge thank you to Stanford for hosting such an insightful gathering, and to all the attendees for pushing the conversation forward. Ronjon Nag, Amit Sharma and Stephanie D. from Lifespan Research Institute, Colwyn Headley, PhD, Helen Blau, Christopher Rhodes from Mimio Health, Martin Kawalski, MD, PhD, Chris Hanson from Olfactive Biosolutions, Jonathan Z. Long, Dr Katarzyna Molenda Wasilewska from University of Cambridge, Dan Gomari from iollo, Maddalena Adorno from Dorian Therapeutics.

Rubedo Life Sciences, one of LongeVC’s portfolio companies, is transitioning into a clinical-stage, and announced Phase 1 clinical trial plans around their lead asset RLS-1496 - a first-in-class GPX4 modulator designed to target aging cells and the surrounding tissues. Rubedo has the opportunity to set a new standard in addressing conditions tied to chronic inflammatory dermatological conditions and in skin aging - paving the way for advancements in many other tissue types to follow. Congratulations to Marco Quarta, Ali Siam, Frederick Beddingfield MD, PhD and the team! Read more about their announcement here: https://lnkd.in/d-ADBzFX  

A diagnosis within minutes can save lives. This is especially true in cases like neonatal sepsis, where every second counts. We are happy to share that Melio, our portfolio company, has received $3.5M in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to continue developing an innovative tool to detect neonatal sepsis with unmatched speed and precision. CARB-X is supported by the Gates Foundation and Biomedical Advanced Research and Development Authority (BARDA). Why does this matter? Sepsis is one of the leading causes of mortality in newborns. Rapid diagnosis is often the difference between life and death. We believe that the future of healthcare is not only about creating better tools but also ensuring those tools are accessible when and where they’re needed most. Congratulations to Mridu Sinha, Stephanie Fraley and the whole team! Read more about Melio & CARB-X funding here: https://lnkd.in/gM_FXdXk

Last year, the biotech industry demonstrated its ability to innovate and adapt, with groundbreaking advancements redefining its potential. 2025 promises to be even more exciting, with continuous innovations in AI-powered drug discovery and personalized medicine transforming how we address healthcare challenges. However, these advancements stem from the decisions and investments that turn ideas into tangible breakthroughs. LongeVC’s Artem A. Trotsyuk shared his insights on these developments in a recent, well-researched article by Willow Shah-Neville for Labiotech.eu. Artem highlighted the increasing trend of larger companies acquiring smaller biotech firms to access new medicines and technologies, particularly as older drug patents expire. He noted, “Even medium-sized companies are now purchasing other firms, indicating that this trend is on the rise.” For a deeper exploration of the trends shaping the future of biotech, read the full article here: https://lnkd.in/dZrDAdhM